Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Stocks | Futures | Watchlist | More
or

Syndax Pharma (SNDX)

Syndax Pharma (SNDX)

[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 240,460
  • Shares Outstanding, K 27,140
  • Annual Sales, $ 1,520 K
  • Annual Income, $ -73,960 K
  • 60-Month Beta 2.40
  • Price/Sales 156.90
  • Price/Cash Flow N/A
  • Price/Book 5.40

Analyst Rating / Earnings Estimates

Current Rating
See More
Strong Buy
Based on 4 analysts offering recommendations.
Earnings Estimates - Current Qtr 12/31/19
See More
  • Average Estimate -0.47
  • Number of Estimates 4
  • High Estimate -0.41
  • Low Estimate -0.52
  • Prior Year -0.70
  • Growth Rate Est. (year over year) +32.86%

Price Performance

See More
Period Period Low Period High Performance
1-Month
6.40 +38.44%
on 11/13/19
9.47 -6.44%
on 12/06/19
+1.85 (+26.39%)
since 11/12/19
3-Month
5.35 +65.61%
on 11/08/19
9.47 -6.44%
on 12/06/19
-0.20 (-2.21%)
since 09/12/19
52-Week
3.39 +161.36%
on 12/26/18
11.11 -20.25%
on 08/13/19
+3.97 (+81.19%)
since 12/12/18

Most Recent Stories

More News
Syndax Pharmaceuticals Announces Plans to Commence Phase 2 Expansion Cohort of SNDX-6352 for the Treatment of Chronic Graft Versus Host Disease

Syndax Pharmaceuticals, Inc. ("Syndax," the "Company" or "we") (Nasdaq: SNDX), a clinical stage biopharmaceutical company developing an innovative pipeline of cancer therapies, today announced that it...

SNDX : 8.86 (+1.03%)
Syndax Announces Preclinical Results Supporting Development of its Portfolio of Menin Inhibitors In Mixed Lineage Leukemias

Syndax Pharmaceuticals, Inc. ("Syndax," the "Company" or "we") (Nasdaq: SNDX), a clinical stage biopharmaceutical company developing an innovative pipeline of cancer therapies, today announced the publication...

SNDX : 8.86 (+1.03%)
Syndax Pharmaceuticals (SNDX) Reports Q3 Loss, Misses Revenue Estimates

Syndax (SNDX) delivered earnings and revenue surprises of 14.58% and -0.26%, respectively, for the quarter ended September 2019. Do the numbers hold clues to what lies ahead for the stock?

SNDX : 8.86 (+1.03%)
Syndax Pharmaceuticals Reports Third Quarter 2019 Financial Results and Provides Clinical and Business Update

Syndax Pharmaceuticals, Inc. ("Syndax," the "Company" or "we") (Nasdaq: SNDX), a clinical stage biopharmaceutical company developing an innovative pipeline of cancer therapies, today reported its financial...

SNDX : 8.86 (+1.03%)
Syndax Announces First Patient Dosed in Phase 1/2 AUGMENT-101 Trial of SNDX-5613 for the Treatment of Adults with Relapsed/Refractory Acute Leukemias

Syndax Pharmaceuticals, Inc. ("Syndax," the "Company" or "we") (Nasdaq: SNDX), a clinical stage biopharmaceutical company developing an innovative pipeline of cancer therapies, today announced that the...

SNDX : 8.86 (+1.03%)
Syndax to Announce Third Quarter 2019 Financial Results and Host Conference Call and Webcast on November 7, 2019

Syndax Pharmaceuticals, Inc. ("Syndax," the "Company" or "we") (Nasdaq:SNDX), a clinical stage biopharmaceutical company developing an innovative pipeline of cancer therapies, announced today that it will...

SNDX : 8.86 (+1.03%)
JDRF T1D Fund Appoints Veteran Life Sciences Executive Dr. Steven St. Peter as Managing Director

The JDRF T1D Fund, the venture philanthropy fund focused on accelerating life-changing solutions to cure, prevent, and treat type 1 diabetes (T1D) through catalytic investments, today announced the expansion...

PETX : 4.92 (-0.20%)
RYTM : 24.91 (+0.61%)
SNDX : 8.86 (+1.03%)
PRTO : 0.32 (unch)
Implied Volatility Surging for Syndax (SNDX) Stock Options

Investors need to pay close attention to Syndax (SNDX) stock based on the movements in the options market lately.

SNDX : 8.86 (+1.03%)
Syndax Announces Participation at Four Upcoming Investor Conferences

Syndax Pharmaceuticals, Inc. ("Syndax," the "Company" or "we") (Nasdaq:SNDX), a clinical stage biopharmaceutical company developing an innovative pipeline of cancer therapies, today announced that members...

SNDX : 8.86 (+1.03%)
Syndax Pharmaceuticals (SNDX) Reports Q2 Loss, Lags Revenue Estimates

Syndax (SNDX) delivered earnings and revenue surprises of -6.82% and -2.82%, respectively, for the quarter ended June 2019. Do the numbers hold clues to what lies ahead for the stock?

SNDX : 8.86 (+1.03%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 24% Buy with a Average short term outlook on maintaining the current direction.

Long term indicators fully support a continuation of the trend.

See More Share

Trade SNDX with:

Business Summary

Syndax Pharmaceuticals, Inc. is a biopharmaceutical company which focused on the development and commercialization of entinostat, an epigenetic therapy for treatment-resistant cancers. The Company's product pipeline includes ENCORE 601, ENCORE 602, J1353, NCI-7870, NCI-9844, E2112, NCI-8871 and NCI-9253...

See More

Key Turning Points

2nd Resistance Point 9.34
1st Resistance Point 9.10
Last Price 8.86
1st Support Level 8.69
2nd Support Level 8.52

See More

52-Week High 11.11
Last Price 8.86
Fibonacci 61.8% 8.16
Fibonacci 50% 7.25
Fibonacci 38.2% 6.34
52-Week Low 3.39

See More

Want to use this as
your default charts setting?
Learn about our Custom Templates
Switch the Market flag
above for targeted data.
Open the menu and switch the
Market flag for targeted data.
Get Streaming Chart Updates
Switch your Site Preferences
to Interactive Chart
Read About Upcoming
Changes to This Feature
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.

Free Barchart Webinar